Advancing Patient Care: New Clinical Evidence Supports Camstent Coated Catheters

At Pennine Healthcare, we are committed to delivering innovative medical solutions that enhance patient outcomes while supporting healthcare providers in tackling ongoing clinical challenges. We are pleased to highlight the publication of a new UK multicentre clinical study evaluating Camstent’s coated catheter technology.

New Clinical Evidence Published

On 9 April 2026, Camstent announced the publication of a clinical study in the journal Antibiotics (MDPI). The findings provide compelling evidence supporting the effectiveness of Camstent Coated Catheters (CCCs) compared to standard care.

The study demonstrated significantly higher infection-free rates among patients using CCCs:

• 79% infection-free at Day 7 compared to 46% with standard care
• 69% infection-free at Day 14 compared to 39% with standard care

Particularly noteworthy were results in long-term catheterised patients, where:

• No symptomatic CAUTIs were observed in the CCC group
• 20% incidence was recorded in the standard care group

Additionally, antibiotic use for urinary tract infections was substantially reduced:

• 4.3% in CCC patients vs. 21.1% in standard care

These findings reinforce the growing need for innovative, non-antibiotic solutions that improve patient outcomes while supporting antimicrobial stewardship efforts.

The Role of Innovation in Infection Prevention

Traditional approaches to preventing CAUTIs, such as antibiotic prophylaxis and standard catheter care, have not fully eliminated infection risk. The results of this study highlight the clinical value of newer technologies like Camstent’s coated catheter, which address the root causes of infection rather than relying solely on reactive treatments.

Introducing the Camstent BACTERIA-PHOBIC® Coated Foley Catheter

The Camstent BACTERIA-PHOBIC® coated Foley catheter is designed to reduce infection risk while maintaining ease of use in clinical settings.

Its coating technology works by repelling bacteria, helping to prevent biofilm formation and reduce infection-related complications such as discomfort, prolonged hospital stays, and increased antibiotic use. As a non-pharmacological solution, it also supports antimicrobial stewardship by avoiding the use of antibiotics.

Key Benefits

• Repels bacteria to help prevent biofilm formation
• Reduces the risk of catheter-associated infections
• Non-antibiotic approach, helping to limit antimicrobial resistance
• Smooth, micro-thin coating designed to minimise irritation and improve patient comfort
• Durable coating that remains effective throughout use
• Meets sterility, biocompatibility, CE and UKCA standards
• No changes to standard handling or clinical practice required

Pennine Healthcare & Camstent Partnership

Pennine Healthcare is proud to distribute the Camstent BACTERIA-PHOBIC® coated Foley catheter, supporting the availability of innovative, clinically evidenced solutions across UK healthcare settings. This latest study further highlights the importance of continued research and collaboration in improving patient outcomes and advancing standards of care. If you’re interested, read the full paper here: https://www.mdpi.com/2079-6382/15/4/369

(Camstent will submit the findings from this paper to their Notified Body)